Forward Flow Test with Percent Rejection

to 3.6 drub in a syringe-applicator with a protective mechanism number 1, cap. The main effect of pharmaco-therapeutic effects of drugs: an analog of natural gonadotropin - releasing hormone Cyclic Adenosine Monophosphate with enhanced biological activity, after re-entry significantly inhibited secretion of gonadotropins and gonad steroids, for a complete inhibition of testicular testosterone synthesis, efficiency buserelinu identical orhiektomiyi (benefit is the reduction and reflexivity psychological stress for the patient). Dosing and Administration of drugs: injected V / m or p / w 1 per month, the injection time to modify; prostate cancer: single dose is 3.75 mg or 7.5 mg endometriosis and uterine fibroids - 3 75 mg (for women of reproductive age first injection administered on Day 3 of menstruation), duration of treatment - no more than 6 months; Mr injection prepared immediately before administration, using the solvent in the concentration of 3.75 mg / 1 ml drub . Indications for use drugs: inoperable or metastatic breast cancer or endometrial cancer (palliative treatment). Pharmacotherapeutic group: L02AE01 - analogues of gonadotropin - releasing hormone. Pharmacotherapeutic group: L02AE02 - analogues of gonadotropin-releasing hormone. Method of production of drugs: suspension for injection, drub mg / ml to 3.3 ml (500 mg) in 6.7 ml (1000 mg) vial. Contraindications to the use of drugs: thrombophlebitis, thromboembolic disorders, cerebral apoplexy or having a history of these diseases, vaginal bleeding unknown origin, liver dysfunction or disease, severe cardiac dysfunction, hypertension, allergy to the active ingredient or any component of the drug, pregnancy and lactation. for p / w input prolonged by 3.6 mg or 10.8 mg in a syringe-applicator with a protective mechanism number 1. Indications for use drugs: progressive prostate cancer (palliative treatment), including (in ineffectiveness or inability orhiektomiyi / estrogen treatment), endometriosis, uterine fibroids, as well as symptomatic treatment and improvement of women in menopause who refused surgery (see the "Obstetrics and Gynecology.